In Brief: Baxter
This article was originally published in The Gray Sheet
Executive Summary
Baxter: Firm's Vascular Systems Division signs exclusive license agreement with researchers at the University of Sydney, Australia, to commercialize a minimally invasive vascular graft system for the repair of abdominal aortic aneurysms. Terms of the agreement were not disclosed. The system, developed by Geoffrey White, MD, and Weiyun Yu, BS, uses a catheter to deliver the graft to the site of the aneurysm, where the graft seals the aneurysm, creating a "new channel for blood to flow through the aortic artery," Baxter says. Clinical trials of the device are slated to begin in Europe in the fourth quarter of 1996; U.S. trials are expected to commence in 1997 following FDA approval of an investigational device exemption...
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.